eCommons@AKU
Internal Medicine, East Africa

Medical College, East Africa

10-2020

Adult secondary hemophagocytic lymphohistiocytosis
Antonina Obayo
Karishma Sharma
Caroline Mithi
Riyat Malkit
Anne Mwirigi

Follow this and additional works at: https://ecommons.aku.edu/eastafrica_fhs_mc_intern_med
Part of the Hematology Commons, and the Internal Medicine Commons

Received: 10 September 2020

Revised: 24 September 2020

Accepted: 25 September 2020

DOI: 10.1002/jha2.113

SHORT REPORT

Adult secondary hemophagocytic lymphohistiocytosis
Antonina Obayo1
Anne Mwirigi2

Karishma Sharma1

Caroline Mithi1

Malkit Riyat2

1

Department of Medicine, Faculty of Health
Sciences, Aga Khan University Medical College
of East Africa, Nairobi, Kenya

Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive
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inflammation and tissue destruction due to abnormal immune activation. HLH carries
a very high mortality, and while delays in patients’ presentation to hospital, time to suspicion of HLH, investigation, and initiation of therapy all play a part, mortality remains
high even with timely diagnosis and treatment. Classical manifestations of HLH include
persistent fever, cytopenias, and liver dysfunction.
Case presentation: We present four cases of secondary HLH, highlighting the demographic and clinical characteristics of these patients, underlying triggers (including systemic lupus erythematosus, lymphoproliferative disorders, and leishmaniasis),
together with challenges associated with the diagnosis and treatment of this rare disorder and a brief review of literature.
Conclusion: HLH has protean manifestations and requires a high index of suspicion as
it can be a great clinical masquerader. Mortality due to multiorgan failure is often high
even with early recognition and treatment.
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lymphohistiocytosis,

INTRODUCTION

HLH-2004

diagnostic

criteria,

systemic

lupus

1/LYST), Griscelli syndrome type 2 (RAB 27A), Hermansky-Pudlak
syndrome type 2 (AP3B1), and the X-linked lymphoproliferative

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of exag-

syndromes XLP-1 (SAP) and XPL-2 (XIAP) [2].

gerated inflammatory response and tissue destruction due to

Secondary (sporadic, acquired) HLH occurs in patients without a

abnormal immune activation [1]. It can occur as a familial or spo-

known familial mutation, in some of whom a clear trigger for devel-

radic disorder, and may be triggered by various immune activating

opment of HLH can be identified. Acquired or secondary cases of

events.

HLH can be broadly triggered by malignancy, infectious, or autoim-

Primary HLH or familial hemophagocytic lymphohistiocytosis (FHL)

mune etiology [2–4]. Commonly, these include Epstein-Barr virus

refers to HLH caused by gene mutations and presents in childhood.

(EBV), cytomegalovirus (CMV), lymphoproliferative disorders and

Identifiable causes include the following mutations: 9q21.3-22, PRF-1,

connective tissue disorders, such as systemic lupus erythematosus

UNC 13D, STX 11, and STX BP2, Chediak-Higashi syndrome (CHS-

(SLE).
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METHODS AND MATERIALS

We conducted a retrospective review of the patient charts of four

TA B L E 1 Initial investigations at admission for patient A.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine
aminotransferase; AST, aspartate aminotransferase;
GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase

patients, who were diagnosed with HLH at the Aga Khan University
Hospital, Nairobi between 2018 and 2019. The diagnosis of HLH was
based on the HLH-2004 guidelines that require five of eight criteria to
qualify for a diagnosis of HLH.

Initial investigation

Value

Reference
range

Hemoglobin

8.6 g/dL

11.5-16.5

(hemoglobin < 9 g/dL, platelets < 1009 /L, neutrophil count < 19 /L),

MCV

79.60 fL

77-93

hypertriglyceridemia and/or hypofibrinogenemia, hemophagocytosis

MCH

27.40 pg

27-33

These criteria include fever, cytopenias affecting two lineages

on biopsy of bone marrow, spleen or lymph node, hyperferritine-

Hematocrit

22.2%

37-47

mia > 500 ng/mL, impaired natural killer (NK) cell activity, and elevated

Reticulocyte count

0.11%

0.2-2

CD 25 (soluble interleukin 2 receptor).

Total leucocyte count

0.85 × 109 /L

4-10

Peripheral blood film

Target cells and tear drop
cells. Markedly reduced
platelets. No schistocytes.

Platelet count

4.00 × 109 /L

3

CASE PRESENTATION AND RESULTS

3.1

Case A

A 30-year-old male patient was referred to our outpatient department
following treatment for neutropenic sepsis and bone marrow failure

150-400

Lactate dehydrogenase

890 U/L

135-214

AST

186.60 U/L

0-35

ALT

355.40 U/L

0-35

ALP

171.00 U/L

0-98

fatigue, unexplained weight loss, and fevers as the predominant symp-

GGT

115 U/L

0-35

toms. There had been severe anemia necessitating blood transfusion,

Total bilirubin

43 U/L

0-21

easy bruising, and evidence of mucosal hemorrhage, with gum bleeding

Direct bilirubin

31 U/L

0-3.4

and frank haematuria.

Albumin

23.5 g/L

35-55

Ferritin

16 731 ng/mL

13-150

Serum potassium

3.55 mmol/L

3.3-5.4

Serum creatinine

50 Umol/L

58-96

Serum bicarbonate

20.5 mmol/L

22-29

Serum sodium

141 mmol/L

135-145
2.1-7.1

at a peripheral facility. He had been unwell for 2 months prior, with

Initial assessment revealed temperature of 39◦ C, heart rate (HR)
of 80/minute, respiratory rate (RR) of 20/minute, and blood pressure
(BP) of 90/60 mm Hg. The physical examination was significant for hepatosplenomegaly. Initial investigations at time of admission are summarized in Table 1.
A computerized tomography (CT) scan of the chest and abdomen
revealed features of pulmonary edema, scattered ground glass opaci-

Blood urea nitrogen

9.6 mmol/L

ties, and gross splenomegaly of 20 cm.

Hepatitis C antibody

Negative

Hepatitis B surface antigen

Negative

Despite broad-spectrum antibiotic therapy, the patient remained
febrile. Blood cultures were unrevealing for any microbial growth.
Aphaeretic platelet transfusions were required, despite which he had
persistent thrombocytopenia. Prothrombin time/international normalized ratio (PT/INR) was within normal limits, making disseminated
intravascular coagulation (DIC) unlikely.
While serum vitamin B12 and serum folic acid levels were normal, hematinic studies were significant for hyperferritinemia with
ferritin >16 000 ng/mL, immediately raising the suspicion of HLH.
Additional target investigations gave serum triglycerides 5.28 mmol/L
(normal 0.3-1.7), LDH 1807 U/L, and a steep rise of ferritin
75 330 ng/mL within 2 days of diagnosis.
According to the HLH-2004 trial, this patient fulfilled the diagnostic
criteria for HLH, with six out of the eight points: fever T > 38.5◦ C, bicy-

Despite high doses of dexamethasone and etoposide (100 mg/mš) as
per the HLH -94 treatment protocol, his condition deteriorated further,
with worsening respiratory distress, acute liver failure, and progressive
confusion. He passed on despite prolonged resuscitative efforts on the
12th day of admission.
By the time the results of the bone marrow trephine biopsy were
available, the patient had passed on. The trephine biopsy revealed a
diagnosis of EBV-positive Classic Hodgkin’s lymphoma, in addition to
CD68 positive scattered histiocytes throughout the bone marrow. In
tandem with this, results of EBV serology nuclear antigen (EBNA) IgG
were received and were positive at 600 (negative < 5).

topenia, splenomegaly on abdominal CT scan, hypertriglyceridemia,
and hyperferritinemia. On the Modified 2009 HLH diagnostic score, four

3.2

Case B

of four clinical criteria (fever, splenomegaly, cytopenias, and hepatitis)
and one of four laboratory criteria (hyperferritinemia) were met. His H

A 47-year-old woman presented with a 2-week history of general-

score was 258 points, assigning a 99.6% probability of having HLH.

ized body weakness. She had been diagnosed with and treated for
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malaria at a peripheral facility. She also had new onset acute kidney injury, which had been attributed to malaria. Initial assessment at

TA B L E 2

Initial Lab investigations for Patient B

our facility revealed temperature of 38.5◦ C, HR 100/min, RR 20/min,

Initial
investigation

and BP 155/89 mm Hg. Her abdominal examination was significant

Hemoglobin

7.8 g/dL

11.5-16.5

MCV

79.4 fL

77-93

MCH

29.2 pg

27-33

for splenomegaly. Initial investigations at presentation are shown in
Table 2.
During the initial workup for anemia, ferritin was noted to be
markedly elevated at 1794 ng/mL, which prompted further workup for
possible inflammatory causes, namely bacterial infection, connective
tissue disease and though lower on the list of possibilities, HLH.
Investigations for an infectious etiology revealed a negative malaria
screen, elevated C-reactive protein (CRP) level 82 mg/L, rising serum
lactate dehydrogenase (LDH) to 2149 U/L, and blood cultures unrevealing of any microbial growth.
The connective tissue screen revealed a positive antinuclear anti-

Hematocrit

13.7%

37-47

4.49%

0.2-2

Total leucocyte
count

9.7 × 109 /L

4-10

Platelet count

326.00 × 109 /L

150-450

Peripheral blood
film

Mild auto agglutination with
target cells, basophilic
stippling of RBC and left
shift of granulocytes.
Adequate platelets.

Lactate
dehydrogenase

994 U/L

135-214

plement C3, while C4 was low normal at 0.11 g/L (normal 0.1-0.4).
of 3+. This gave her a score of 13 on the 2018 SLE criteria from EULAR

Reference
range

Reticulocyte
count

body (ANA) in a speckled pattern: titer 1:160, reduced levels of comAnti-ds-DNA and ENA were negative. Urinalysis revealed proteinuria

Value

(European League Against Rheumatism) and ACR (American College of

AST

43.6 U/L

0-35

Rheumatology). The criteria require that a patient have ANA titer of at

ALT

16.3 U/L

0-35

least 1:80 along with 10 points from the clinical and laboratory criteria

ALP

182 U/L

0-98

for a diagnosis of SLE.
A few days after admission, the ferritin level had risen from 1794

GGT

164 U/L

0-35

Total bilirubin

28.9 U/L

0-21

to 6929 ng/mL on admission and there was hypertriglyceridemia of
Direct bilirubin

12.9 U/L

0-3.4

Albumin

26.1 g/L

35-55

A CT scan of the chest and abdomen revealed mild hepatomegaly

Malaria antigen

Negative

and splenomegaly of 15 cm with subcentimeter nodes above and below

Malaria parasite

Absent

the diaphragm.

Direct Coomb’s
test

Negative

revealed hypercellular marrow with features of erythroid hyperplasia

Ferritin

1794 ng/mL

13-150

and reactive histiocytosis.

Folate

10.75 ng/mL

Deficient < 3

3.24 mmol/L (normal 0.3-1.7) and falling platelets to a nadir of 103.00
× 109 /L.

A bone marrow examination performed on the fifth day of admission

According to the HLH-2004 trial, this patient fulfilled the criteria
for a diagnosis of HLH, with five features out of the eight-point diagnostic criteria: persistent fever > 38.5◦ C, bicytopenia, splenomegaly
on an abdominal CT scan, hypertriglyceridemia, and hyperferritinemia.
Modified 2009 HLH diagnostic criteria: four of four clinical criteria (fever,
splenomegaly, cytopenias, and hepatitis), and one of four laboratory

Vitamin B12

624.7 pg/mL

191-663

Serum iron

8.52 Umol/L

6.6-26

Serum potassium

5.02 mmol/L

3.3-5.4

Serum creatinine

141 Umol/L

58-96

Serum
bicarbonate

19.1 mmol/L

22-29

Serum sodium

128 mmol/L

135-145

Blood urea
nitrogen

7 mmol/L

2.1-7.1

Hepatitis B
surface antigen

Positive

Hepatitis C
antibody

Negative

Hepatitis B viral
load

817 IU/mL

Hepatitis B
E-antigen

Negative

criteria (hyperferritinemia) were met. Her H score was 193 assigning
a probability of 82.9% of having HLH.
A diagnosis of HLH due to SLE was made.
Treatment with high doses of steroids was initiated (methylprednisone 500 mg once a day for 3 days), and while she was clinically stable, laboratory parameters worsened, with rising ferritin from 4433
to 6929 ng/mL and falling platelets and LDH levels from 1520 to
2149 U/L. In view of this, a weekly course of rituximab, which is recommended in complicated SLE, was initiated, along with tenofovir, for
the chronic hepatitis B infection.
She responded well to this therapy, with resolution of the fever and
reduction of the inflammatory markers. Subsequently, she was started
on definitive treatment for SLE with hydroxychloroquine and mycophenolate mofetil, and continues to do well on this therapy 10 months later.
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TA B L E 3

Initial Lab investigations for Patient C

Initial
investigation

Value

Reference
range

Hemoglobin

10.8 g/dL

11.5-16.5

MCV

78 fL

77-93

MCH

27pg

27-33

Hematocrit

31.4%

37-47

Reticulocyte
count

2.37%

0.2-2

Total leucocyte
count

1.49 × 109 /L

4-10

Platelet count

5 .00 × 109 /L

Peripheral blood
film

Mild anisopoikilocytosis,
marked leukopenia and
markedly reduced
platelets. No schistocytes

Lactate
dehydrogenase

1140 U/L

135-214

Fibrinogen

1.1 g/L

2-4

AST

299.4 U/L

0-35

ALT

38 U/L

0-35

ALP

346 U/L

0-98

GGT

213 U/L

0-35

Total bilirubin

20.6 U/L

0-21

rest of the physical examination was unremarkable. Initial investiga-

Direct bilirubin

15.5 U/L

0-3.4

tions at the time of the presentation are shown in Table 3.

Albumin

22.2G/L

35-55

Malaria antigen

Absent

dency unit (HDU) with a working diagnosis of septic shock and treat-

Malaria parasite

Absent

ment commenced with broad-spectrum antibiotics. A bone marrow

Ferritin

66567 ng/mL

13-150

Serum iron

14.8 Umol/L

6.6-26

Serum potassium

4.61 mmol/L

3.3-5.4

Serum creatinine

79 Umol/L

58-96

Serum
bicarbonate

22.6 mmol/L

22-29

Serum sodium

131 mmol/L

135-145

persistent fever > 38.5◦ C, pancytopenia, splenomegaly, hypertriglyc-

Blood urea
nitrogen

9.5 mmol/L

2.1-7.1

eridemia of 5.22 mmol/L, hyperferritinemia, and increased histiocytic

Hepatitis B
surface antigen

Negative

Hepatitis C
antibody

Negative

HIV

Negative

FIGURE 1

Leishmania donovani bodies in bone marrow aspirate

In our emergency room, he was found to be pale and had scleral
icterus. Initial assessment revealed temperature 38.7◦ C, HR 87/min,
RR 20/min, and BP 90/58 mm Hg. Apart from hepatosplenomegaly, the

He received fluid resuscitation and was admitted to the high depen-

biopsy performed on the first day of admission for severe pancytopenia revealed extracellular and intracellular Leishmania donovani bodies, increased histiocytic activity, and evidence of hemophagocytosis
(Figures 1 and 2).
His H score was 303 points assigning a 99.97% probability of having
HLH. According to the HLH-2004 trial, this patient fulfilled the diagnosis, with six features out of the eight-point diagnostic criteria for HLH:

activity on a bone marrow aspirate, on which there was also evidence of
L. donovani bodies, clinching the overall diagnosis; HLH was secondary
to visceral leishmaniasis.
He was started on liposomal amphotericin B for 10 days alongside pulsed methylprednisone at 250 mg daily for 4 days, despite
which he developed worsening respiratory distress that progressed
to ARDS, requiring intubation and mechanical ventilation. He developed DIC, and blood stained endotracheal aspirates, which coupled

3.3

Case C

with increasing ventilator requirements, were suggestive of alveolar
hemorrhage.

A 25-year-old male presented with a 4-week history of weight loss,

His stay in the ICU was complicated by multiorgan dysfunction sec-

fevers, fatigue, diarrhea, vomiting, and abdominal pain. He had been

ondary to Klebsiella pneumoniae and coagulase negative staphylococ-

treated at a peripheral facility with artemether lumefantrine for sus-

cal septicemia, acute kidney injury, and refractory DIC, which failed to

pected malaria, and also received broad-spectrum antibiotics (ceftriax-

respond to aggressive treatment, leading to his demise 15 days after

one and doxycycline).

admission.
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TA B L E 4

Initial laboratory investigations for patient D

Initial investigation

FIGURE 2
macrophage

Hemophagocytosis of erythrocytes inside the

Value

Reference
range

Hemoglobin

4.2 g/dL

11.5-16.5

MCV

75 fL

77-93

MCH

25 pg

27-33

Hematocrit

13.7%

37-47

Reticulocyte count

11.54%

0.2-2

Total leucocyte count

18.58 × 109 /L
(neutrophilia, bicytopenia,
and no schistocytes)

4-10

Platelet count

65.00 × 109 /L

Peripheral blood film

Mild autoagglutination,
anisopoikilocytosis,
spherocytes, and reduced
platelets.

Lactate
dehydrogenase

1669 U/L

135-214

Fibrinogen

3.04 g/L

2-4

AST

146.60 U/L

0-35

ALT

19.1 U/L

0-35

ALP

54 U/L

0-98

GGT

30 U/L

0-35

Total bilirubin

14.1 U/L

0-21

A 27-year-old patient presented with fever and chills, headaches,

Direct bilirubin

5.3 U/L

0-3.4

shortness of breath on exertion, nausea, and joint pains of 2 days dura-

Albumin

33.7 g/L

35-55

tion. She had been treated for presumed malaria a week prior to her

Malaria antigen

Positive

presentation to us.

Malaria parasite

Absent

Direct Coomb’s test

Positive

Ferritin

54 396 ng/mL

13-150

Folate

>20 ng /mL

Deficient < 3

Vitamin B12

376 pg/mL

191-663

3.4

Case D

Clinical examination at admission was significant for temperature
38◦ C, dark macular patches over the abdominal wall and limbs, the
latter of which had been present for about 10 months, and hepatosplenomegaly. Initial laboratory investigations at the time of the presentation are shown in Table 4.

Serum iron

14.8 Umol/L

6.6-26

Serum potassium

4.47 mmol/L

3.3-5.4

pected arthritis. At the time, she had mild anemia (hemoglobin 10 g/dL),

Serum creatinine

86 Umol/L

58-96

for which iron supplementation had been recommended.

Serum bicarbonate

15 mmol/L

22-29

Serum sodium

128 mmol/L

135-145

Blood urea nitrogen

7 mmol/L

2.1-7.1

She gave a history of having sought medical attention for joint pains
a year previously, but had not received specific treatment for this sus-

Investigation of the severe anemia revealed a positive direct
Coomb’s test and an elevated LDH 1660 IU, initially suggestive of
hemolysis. However, the hematinic screen gave marked hyperferritinemia, of >50000 ng/mL, which was alarming and prompted a diagnostic workup for HLH. This gave serum fibrinogen level 3.04 g/L, and
serum triglyceride level of 3.88 mmol/L, while serum LDH rose to
3965 U/L.

Blood cultures assessed after 5 days were unrevealing for any
microbial growth. Bone marrow biopsy was performed on the fourth

Due to fever, elevated CRP 72 mg/mL, and procalcitonin 10.5 ng/mL,

day of admission, which showed increased hemophagocytic activity

broad-spectrum antibiotics were initiated. The quantitative buffy coat

corroborated by an increase in CD68 positive histiocytes. Given the

test for malaria was positive and so she was initially managed for

longstanding joint pains and skin lesions, an autoimmune screen was

malaria, with intravenous artesunate. However, both thick and thin

requested.

films were subsequently negative for malaria parasite within 24 h of

According to the HLH-2004 trial, this patient fulfilled the diagno-

admission, as was the malaria antigen test. This, and the fact that there

sis, with six features out of the eight-point diagnostic criteria for HLH,

was no history of travel to a malaria endemic area, made the diagnosis

including a persistent fever >38◦ C, bicytopenia, splenomegaly, hyper-

of malaria unlikely.

triglyceridemia, hyperferritinemia, and a histiocytic activity on a bone
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TA B L E 5

This table provides the demographic and clinical characteristics of the four patients at the time of diagnosis with HLH

CASE

A

B

C

D

Gender

Male

Female

Male

Female

Time of onset of symptoms to
referral

2 months

2 weeks

4 weeks

1 week

Age at diagnosis

30

47

25

27

Fevers

Yes

Yes

Yes

Yes

Splenomegaly

Yes

Yes

Yes

Yes

Cytopenias

Pancytopenia

Bicytopenia

Pancytopenia

Pancytopenia

Ferritin > 500 ng/mL

16 731

1794

66 567

54 396

Triglyceridemia > 3 mmol/L

5.28

3.24

3.78

3.88

Transaminitis

Yes

yes

Yes

Yes

Hemophagocytosis on bone marrow

Yes

No

Yes with Leishmania
donovani bodies

Yes

HLH 2004 sore

6

5

6

6

H score

258

193

303

243

Associated Infections/malignancy/
autoimmune condition

Classic Hodgkin’s
lymphoma

SLE

Leishmaniasis

SLE

Type of therapy

Etoposide and
dexamethasone

Methylprednisone and
rituximab

Amphotericin B and
methylprednisone

Methylprednisone

Outcome

Dead

Alive

Dead

Dead

Abbreviation: HLH, hemophagocytic lymphohistiocytosis; SLE, systemic lupus erythematosus.

marrow aspirate. Her H score was 243 points assigning a 99.1% proba-

of HLH. The clinical and laboratory characteristics are summarized in

bility of having HLH.

Table 5.

She was clinically stable, reporting that she felt better within 48 h of

All patients had deranged liver transaminases at presentation with

admission. However, transient confusion was noted, overnight, which

elevated AST levels. Three patients had hemophagocytosis on bone

had settled by the following morning.

marrow, while the fourth had an increase in the number of histi-

Four days into her admission, and after the first dose of methylpred-

ocytes. Leishmania donovani bodies were present in the bone mar-

nisolone and red cell transfusion, she suffered a tonic clonic seizure,

row of one patient alongside the hemophagocytosis. Soluble IL 2

suffered a cardiac arrest, and died despite prolonged resuscitation

and NK cell testing are not available in our country hence were not

attempt.

tested.

Results of the autoimmune screen were obtained 1 day later, and

A secondary cause of the HLH was identified in all of the patients;

gave positive ANA in a speckled pattern, negative double-stranded

two had previously undiagnosed and untreated SLE, one visceral leish-

DNA (dsDNA), while the extractable nuclear antigen was positive for

maniasis and the fourth classic EBV-driven Hodgkin’s lymphoma.

both anti-Sm and anti-RNP, clinching the diagnosis in this case to be
HLH in a patient with untreated SLE.
Transient confusion while on the ward coupled with a seizure prior

5

DISCUSSION

to death are highly suggestive of CNS HLH, which carries a dire prognosis.

HLH is a syndrome of excessive inflammation and tissue destruction due to abnormal immune activation. HLH is on the spectrum
of macrophage activating syndromes, in which over activation of

4

SUMMARY OF RESULTS

macrophages leads not only to exaggerated cytokine production, but
also to hyperferritinemia, in the release of iron from macrophages, and

The age of the patients ranged from 25 to 47 years (male to female

hemophagocytosis of blood cells [5–8].

ratio 1:1). Fever of undetermined origin, cytopenias, hyperferritine-

The sustained activation of macrophages, NK cells, and cytotoxic

mia, and either splenomegaly or hepatosplenomegaly were prominent

T cells leads to excessive cytokine production. The persistent produc-

features at presentation in each of the cases. All patients met the

tion of cytokines, including interferon gamma, tumor necrosis factor

modified HLH diagnostic criteria according to the HLH-2004 guide-

alpha, interleukins (ILs) such as IL-6, IL-10, and IL-12, and the soluble

lines that require five out of eight criteria to qualify for a diagnosis

IL-2 receptor, further recruits additional inflammatory cells, in a vicious
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cycle, leading to a cytokine storm. This cytokine storm is the primary
mediator of tissue damage [9].
Macrophages are a storage reservoir of ferritin, and this accounts
for high ferritin levels in HLH [10]. Recorded peak ferritin levels greater

TA B L E 6
present

HLH diagnostic criteria; at least five of eight findings
Fever ≥38.5◦ C

1.
2.

Splenomegaly

3.

Ferritin > 500 ng/mL

4.

Peripheral blood cytopenias, with at least two of the
following: hemoglobin < 9 g/dL; platelets < 100.00 ×
109 /L; absolute neutrophil count < 1 × 109 /L

5.

Hypertriglyceridemia (fasting triglycerides > 3 mmol/L)
and/or hypofibrinogenemia (fibrinogen < 150 mg/dL)

6.

Hemophagocytosis in bone marrow, spleen, lymph
node, or liver

The most common presentation of HLH as per the HLH-2004

7.

Low or absent natural killer (NK) cell activity

study included fever, splenomegaly, bicytopenia, hypertriglyceridemia

8.

Elevated soluble CD25 (soluble IL-2 receptor alpha
[sIL-2R]) two standard deviations above
age-adjusted laboratory-specific norms

than 10 000 g/L was found to have a 90% sensitivity and 96% specificity for HLH during a study done at the Texas Children’s Hospital [11].
Therefore, when the clinical and laboratory features are suggestive, a
serum ferritin of >10 000 g/L strongly supports a diagnosis of HLH [2].
This was certainly reflected in three of four cases of this series, where
ferritin, initially performed in assessment of anemia, unexpectedly gave
hyperferritinemia > 10 000 g/L, immediately triggering investigations
for HLH.

or hypofibrinogenemia, hemophagocytosis, ferritin > 500 mcg/L, low
or absent NK cell activity, and soluble CD25 elevation [12]. As summarized above, all four patients described in this series presented with
fever, splenomegaly, hyperferritinemia, and cytopenias.
In the early stages of HLH, hemophagocytosis might not be seen
in the bone marrow. This and the patchy nature of this phenomenon

TA B L E 7

Modified 2009 HLH criteria

Clinical

Three of four clinical findings 1.
2.
3.
4.

in bone marrow samples mean that its absence does not negate HLH
as the diagnosis. The incidence of bone marrow involvement varies
between 25% and 100% [13] and bone marrow analysis for presence
of hemophagocytosis has a sensitivity of around 60% [14]. One of the
patients (Case B) did not have hemophagocytosis on the bone marrow, but did have an excess of histiocytes within the bone marrow. This
probably corresponds with the patient having the "mildest" and possibly earliest form of HLH in the cohort and hence being picked up at the

Fever
Splenomegaly
Cytopenias
Hepatitis

Plus
Immune One of four immune markers 1. Hemophagocytosis
markers
2. Increased ferritin
3. Hypofibrinogenemia
4. Absent or very decreased
NK cell function

earlier than the other cases.
The overall mortality of HLH is high, varying between 26.5 and
74.8%, and depends on the patient characteristics, underlying precipitating conditions, and stage of disease [15]. This was also seen in our

5.2

Triggers of HLH

case series, which reported a high mortality rate, with the only survivor
having been diagnosed at a relatively early stage of the disease course,

In all four cases, a trigger for HLH was identified, but in only one of

and remaining in good health to date.

these cases, characterised by early patient presentation, timely clinical suspicion, work up and treatment resulted in a favourable patient
outcome. Macrophage activation has been reported to be triggered

5.1

Diagnostic criteria

by infections, most commonly viral infections such as EBV [20–22],
and has also been associated with leishmaniasis and CMV [22]. Malig-

The diagnostic criteria is based on the HLH-2004 trial [12,16]. To make

nancies, most commonly lymphoproliferative, are also recognized to

a diagnosis, at least five out of eight findings are required as high-

be activators of the immune system as are autoimmune conditions.

lighted in Tables 6 and 7. All the patients in this case series (100%)

Although a seemingly heterogeneous group of conditions, the disor-

fulfilled both the 2004 and the modified 2009 HLH criteria. Addition-

ders mentioned above all have the ability to activate the immune sys-

ally, the HLH H score was calculated for each patient and gave a high

tem and lead to a macrophage activating syndrome typical of HLH,

probability of HLH in all the patients (99% for cases A, C, D, and for

characteristic of the disordered, exaggerated response, and its resul-

82.9% for case B). The H score is a weighted criteria score, validated

tant tissue damage.

for diagnosis in secondary adult causes of HLH. It is aimed at achieving a more effective estimate of the probability of HLH and consists of

5.3

Treatment

graded clinical and laboratory parameters with a sensitivity and specificity of 90% and 79% [17]. In a retrospective study done to com-

Therapy is based on the HLH-94 protocol [23,24]. The standard treat-

pare the performance of HLH-2004 guidelines with the new H-score,

ment is corticosteroids, to which etoposide is added in cases which

H-score performed better in identifying HLH at presentation among

do not initially respond, and in which no other cause is found for

adult patients [15,18,19].

the HLH, along with identification and treatment of any underlying
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cause. Rituximab is recommended in EBV-driven HLH, with the mech-

In our series, an unexpectedly high ferritin, which in each case was per-

anism of action being eradication of the EBV reservoir through clear-

formed early in course of admission to investigate anemia, resulted in

ance of B cells [15,19]. For central nervous system disease, intrathecal

early suspicion of the condition and relatively early appropriate inves-

methotrexate and hydrocortisone are added to the induction therapy

tigations and treatment for HLH.

[24]. In patients not showing signs of improvement, the above therapy

However, despite benefitting from an early diagnosis and initiation

is continued while planning for allogeneic hematopoietic cell transplan-

of therapy for HLH, vis-a-vis their admission to our facility, three of

tation in suitable cases.

these patients presented with already established macrophage activa-

Patient A had EBV-driven classical Hodgkin’s lymphoma but the
diagnosis was only available postmortem. Additionally, he had been

tion, HLH, and features of organ failure. Therefore, the HLH-directed
treatment, though appropriate, proved futile in these cases.

unwell for a number of months prior to presentation. Despite initiating

The mortality of patients with HLH is very high and delay in diagno-

etoposide and methylprednisolone within days of presentation at our

sis confers the greatest risk to a fatal outcome, as shown in this series

center, he had a rapid clinical deterioration and died. Rituximab ther-

where the time to presentation ranged from 2 weeks to 2 months.

apy would have been a recommendation in his case, had EBV PCR been

This case series highlights the difficulty in obtaining a good outcome

performed and found positive [15,19]. HLH associated with lymphomas

in HLH, even when the diagnosis is suspected early on. Additionally,

tends to have a higher mortality compared to HLH due to infections

HLH was not suspected at peripheral facilities, probably due to a com-

and autoimmune conditions [22]. Worsening cytopenias and cholesta-

bination of factors: (a) it is uncommon and shares features with sepsis,

sis are predictive of death in HLH, and a rapid drop in ferritin levels

which is far more common; (b) ferritin level, which was markedly ele-

after initiation of treatment is associated with improved outcome [25].

vated and prompted a search for HLH at our center, is not widely avail-

Both patients B and D had SLE. However, while patient B had a his-

able at peripheral facilities and can be costly.

tory of symptoms that had been present for approximately 1 month,

It cannot be stressed enough that a high index of suspicion is war-

patient D had symptoms for more than 10 months, and indeed had been

ranted, when faced with a patient with a triad of fever, cytopenias, and

evaluated and found to have joint pains, anemia, and skin lesions at that

organomegaly, which is unexplained, and that checking a ferritin level

time, but had been lost to follow up. Both patients had ferritin assess-

in this case may highlight unexplained hyperferritinemia and lead to

ment early on as part of the investigation of the cause of anemia at pre-

appropriate investigations for HLH. The patients described here were

sentation. Patient B’s ferritin level was 1794 ng/mL, while patient D’s

diagnosed with HLH promptly within our service, partly because we

ferretin level was 54 396 ng/mL.

were able to quickly discount alternative diagnoses as treatment of

A high index of suspicion of HLH in patient B, mainly because there
were no other significant pointers to an alternative pathology led to

these had already been initiated with poor outcome at peripheral facilities.

early initiation of high-dose methylprednisolone, and subsequent posi-

A multidisciplinary approach, including early consultations with a

tive ANA serology allowed for definitive treatment of SLE. This patient

haematologist, either remotely or in person is essential to promptly

responded well to treatment and is now asymptomatic, more than a

investigate and initiate appropriate therapy, which is relatively acces-

year later.

sible. Prompt, lifesaving and timely treatment, is likely to have to be

Although patient D’s elevated ferritin was also investigated

initiated before all test results have been returned, hence relying on a

promptly, hyperferritinemia > 50 000 at presentation is indicative

consensus of clinical and laboratory features compatible with the diag-

of already established macrophage activation, which could not be

nosis, but not yet diagnostic of it.

reversed even with timely treatment. Additionally, the fact that she
had transient neurological symptoms and a generalized seizure is
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highly suggestive of neuro-HLH, which carries a grave prognosis.
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Patient C had a bone marrow diagnosis of leishmaniasis, coupled
with features of advanced HLH. However, he too presented several
weeks after falling ill, and receiving antibiotic therapy for presumed
bacterial infection at another center. Despite high dose of methylprednisolone and amphotericin B, it was impossible to reverse the established HLH and multiorgan failure, which were present at presentation,
leading to his adverse outcome.

6

CONCLUSION

Diagnosis of HLH presents a diagnostic challenge to clinicians due to
the nonspecific signs and symptoms that portend a wide array of differential diagnosis. Therefore, a high index of suspicion is warranted especially when a patient presents with unremitting fevers and cytopenias.
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